By Josée Rose
ALX Oncology is cutting about 30% of its workforce and realigning its focus.
The clinical-stage biotechnology company named Harish Shantharam as chief financial officer and Alan Sandler as chief medical officer.
ALX said its "strategic prioritization and resource optimization" plan, which primarily will affect its preclinical research department, is expected to extend its cash runway into the fourth quarter of 2026. As of Dec. 31, ALX had cash, cash equivalents and investments of $131.3 million.
The company expects results from several Phase 2 trials related to head and neck squamous cell carcinoma in the second quarter.
ALX said its loss for the three months ended Dec. 31 was 55 cents a share, compared with a loss of 93 cents in the year-earlier period, due to lower research and development expenses.
ALX also named Barbara Klencke and Chris Takimoto to its board of directors.
Write to Josée Rose at josee.rose@wsj.com
(END) Dow Jones Newswires
March 06, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。